- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07945795
RDN for CKD and Uncontrolled Hypertension Trial
Effect and Safety of Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease: A Randomized, Sham-control, Blinded, Clinical Trial
Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.
연구 개요
상태
상세 설명
This Prospective, Multi-Center, Randomized, parallel-controlled uptake clinical trial aims to evaluate the efficacy and safety for renal denervation in patients with uncontrolled hypertension and chronic kidney disease, and to provide clinical evidence supporting the expansion of indications.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Luyun Fan
- 전화번호: +86-13522601484
- 이메일: katevan@163.com
연구 연락처 백업
- 이름: Jingjing Zhou
- 전화번호: +86-18742568090
- 이메일: zhoujjrf0901@163.com
연구 장소
-
-
-
Beijing, 중국, 101118
- 모병
- Beijing Anzhen Hospital
-
연락하다:
- Jun Cai
- 전화번호: +86-13810615602
- 이메일: caijun7879@126.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female, aged 18 to 65 years, inclusive, at the time of consent;
- Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and <180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and <170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and <180 mmHg, and 24h SBP ≥130 mmHg and <170 mmHg;
- Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73m² and <60 mL/min/1.73m²;
- The presence or absence of accessory renal arteries is acceptable;
- The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form.
Exclusion Criteria:
- Pregnant or breastfeeding, or planning pregnancy during the study.
- Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter <3 mm, or treatable segment length <20 mm).
- Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis.
- Prior renal artery intervention or prior renal denervation.
- Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.).
- Allergic to contrast agents.
- Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months.
- Orthostatic hypotension.
- Type 1 diabetes mellitus.
- Primary pulmonary arterial hypertension.
- History of bleeding diathesis and haematological disorders or coagulopathy
- History of thromboembolic event within 6 months.
- History of stroke or transient ischemic attack (TIA) within 6 months.
- Severe peripheral arterial disease or unstable abdominal aortic aneurysm.
- Severe valvular heart disease or anticipated need for surgical valve replacement during the study period.
- NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months.
- History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker.
- Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (<0.5 mL·kg-¹·h-¹ for ≥6 hours).
- Severe hepatic dysfunction.
- Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS.
- Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements.
- Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted).
- Acute or severe systemic infection.
- Other conditions deemed unsuitable for participation by the investigator.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Renal Denervation (RDN)
Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months. |
DSA-guided percutaneous renal sympathetic denervation using a RF renal denervation system
다른 이름들:
|
|
가짜 비교기: Parallel control with sham operation
Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months. |
Sham procedure including femoral artery puncture and selective renal angiography; the radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure at Month 6 (ABPM)
기간: Baseline to Month 6 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring; change is Month 6 minus Baseline |
Baseline to Month 6 post-procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in 24-hour Ambulatory Diastolic Blood Pressure at Month 6 (ABPM)
기간: Baseline to Month 6 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Baseline to Month 6 post-procedure
|
|
Change from Baseline in Office Blood Pressure (including both systolic and diastolic BP)
기간: Baseline to Months 1, 3, 6 and 12 post-procedure
|
measured by validated office blood pressure monitoring |
Baseline to Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure (including both systolic and diastolic BP)
기간: Baseline to Months 1, 3, and 12 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Baseline to Months 1, 3, and 12 post-procedure
|
|
Change from Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure (ABPM)
기간: Baseline to Months 1, 3, 6, and 12 post-procedure
|
24-hour mean systolic BP measured in Daytime and Nighttime by validated ambulatory BP monitoring |
Baseline to Months 1, 3, 6, and 12 post-procedure
|
|
Percentage of Participants with 24-hour Ambulatory Systolic BP <130 mmHg
기간: Months 1, 3, 6, and 12 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Months 1, 3, 6, and 12 post-procedure
|
|
Percentage of subjects with office systolic BP within the target ranges (<140 mmHg and <130 mmHg)
기간: Months 6 and 12 post-procedure
|
measured by validated office blood pressure monitoring |
Months 6 and 12 post-procedure
|
|
Responder Rate: ≥5 mmHg Reduction in office Systolic BP
기간: Months 6 and 12 post-procedure
|
Proportion of participants with a reduction ≥5 mmHg from baseline in office BP |
Months 6 and 12 post-procedure
|
|
Change from Baseline in Antihypertensive Medication Use
기간: Months 1, 3, 6 and 12 post-procedure
|
Change in the number of concurrently prescribed antihypertensive agents |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in serum creatinine levels
기간: Months 1, 3, 6 and 12 post-procedure
|
Change in postoperative serum creatinine levels relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Changes from Baseline in glomerular filtration rate
기간: Months 1, 3, 6 and 12 post-procedure
|
Changes in glomerular filtration rate relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Changes from Baseline in the urine microalbumin-to-creatinine ratio
기간: Months 1, 3, 6 and 12 post-procedure
|
Changes in the urine microalbumin-to-creatinine ratio relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in Heart Rate (by ECG)
기간: Months 1, 3, 6 and 12 post-procedure
|
Resting heart rate measured by standard 12-lead ECG; change is Follow-up minus Baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in left ventricular ejection fraction (LVEF) (by Echocardiography)
기간: Months 12 post-procedure
|
by Echocardiography |
Months 12 post-procedure
|
|
Change from Baseline in left ventricular mass index
기간: Months 12 post-procedure
|
by Echocardiography |
Months 12 post-procedure
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- BRWEP2024W012060105
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .